Azenta, Inc. (NASDAQ: AZTA) has reported its financial results for the first quarter ended December 31, 2025. The company's revenue from continuing operations was $149 million, reflecting a 7% decrease from the previous quarter and a 1% increase from the same period last year. The organic growth, which excludes the impact of foreign exchange, declined by 1%.
In terms of segment performance, revenue from sample management solutions was $81 million, down 5% from the previous quarter but remaining flat year over year. The organic revenue for sample management solutions declined by 2%, driven by lower revenues in core products, partially offset by higher revenue in sample storage, product services, and consumables and instruments. Multiomics revenue was $67 million, down 8% from the previous quarter and up 1% year over year. The organic revenue for multiomics was flat year over year.
The company's diluted earnings per share (EPS) from continuing operations improved significantly to ($0.11) from ($0.16) in the first quarter of fiscal year 2025, representing a 27% increase. However, the total diluted EPS decreased to ($0.34) from ($0.25) a year ago, reflecting a 34% decrease.
On a non-GAAP basis, the company's diluted EPS from continuing operations decreased to $0.09 from $0.12, a 24% decline compared to one year ago. Adjusted EBITDA from continuing operations was $13 million, down 39% from the previous quarter and 21% from the same period last year. The adjusted EBITDA margin from continuing operations was 8.5%, a decrease of 230 basis points year over year.
Azenta ended the quarter with a total balance of cash, cash equivalents, restricted cash, and marketable securities of $571 million. The company generated operating cash flow of $21 million, with free cash flow amounting to $15 million.
Looking ahead, Azenta reiterated its guidance for fiscal year 2026, expecting total organic revenue to grow in the range of 3% to 5% relative to fiscal 2025, and adjusted EBITDA margin expansion of approximately 300 basis points relative to fiscal 2025.
Moreover, the company provided an update on the sale of its B Medical Systems business, stating that it entered into a definitive sale and purchase agreement for a purchase price of $63 million, with the transaction expected to close on or before March 31, 2026.
Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance, citing the difficulty in accurately forecasting the occurrence and financial impact of various adjusting items.
The company also announced its share repurchase program, authorizing the repurchase of up to $250 million of the company's common stock through December 31, 2028.
Azenta's management will webcast its first quarter fiscal 2026 earnings conference call today at 8:30 a.m. Eastern Time.
Today the company's shares have moved 0.23% to a price of $40.00. For the full picture, make sure to review Azenta's 8-K report.
